Guardant Health, Inc.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company ended the quarter with approximately $1.2 billion in cash and investments. - They remain focused on disciplined cash management. - They are on track to decrease full year 2026 free cash flow burn compared to 2025. - The company expects to achieve company-wide cash flow breakeven by the end of 2027. - No explicit mention of raising new capital through debt or equity at this time.

- Continued investment in building out the screening sales infrastructure to support Shield and oncology revenue growth (Page 6, 11). - Advancing CDx (companion diagnostics) programs and expanding strategic partnerships with leading biopharma companies (Page 6). - Scaling the InfinityAI platform to enhance AI capabilities and actionable insights using large datasets (Page 10). - Investing in marketing campaigns including DTC (direct-to-consumer) and HCP (healthcare provider) campaigns to drive demand, with reinvestment of incremental gross profit from screening into commercial expansion (Page 11, 13). - Ongoing investments in lab workflow efficiencies and automation expected to reduce Shield cost per test further in 2027 (Page 5). - Planned multiple product launches in 2026 including Reveal Ultra, FDA-approved Guardant360 Liquid, and Smart platform expansion (Page 5). - Potential regulatory-related investments tied to approvals (e.g., camizestrant and FDA clearance of Guardant360 Liquid) representing future growth catalysts (Page 5).

- Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding sales/marketing. - Expect continued hiring of high-quality reps despite competitive field; no pipe-by-pipe sales force updates due to commercial sensitivity. - Shield volumes showing strong acceleration, driven by DTC campaigns, EMR connectivity, and recent Quest partnership. - Guardant360 Liquid expects sustained 20%-30%+ volume growth aided by Smart platform innovation and upcoming FDA approvals. - Reveal product volumes grew over 100% YoY; strong growth expected in CRC, breast, lung cancers, plus therapy monitoring. - Future revenue and volume growth expected from MolDx reimbursement approvals, commercial expansion, and new clinical applications. - ASP for Shield stable around $775-$800, with upward potential as Medicare coverage expands. - Biopharma & Data revenue grew 17% YoY; expanding CDx approvals and InfinityAI-powered insights support growth. - Overall, broad-based, sustained volume growth across portfolio with strategic reinvestment in sales and marketing.

- Full-year 2026 revenue guidance raised to $1.30 - $1.32 billion, representing 32% to 34% growth. - Oncology revenue expected to grow 28% to 29% with volume growth greater than 35%. - Screening revenue expected between $186 million and $198 million, driven by Shield volume of approx. 230,000 to 245,000 tests. - Non-GAAP operating expenses projected at $1.05 billion to $1.07 billion, up 16% to 18% year-over-year. - Full-year free cash flow burn expected to improve to $185 million - $195 million, better than 2025. - Excluding Screening, the business is anticipated to be free cash flow positive for 2026. - The company targets company-wide cash flow breakeven by end of 2027. - Anticipated margin improvements with Shield cost per test expected to decline to ~$200 by 2027. - Potential upside from FDA approvals and reimbursement expansions not included in current guidance.

The provided transcript from page 13 and surrounding content does not mention any specific details about the current or expected order book or pending orders. The discussion focuses primarily on: - Sales force growth and reinvestment strategies. - Product updates such as the FDA approval for the 2-tube Shield test. - Market dynamics and volume growth in oncology products like Reveal and Guardant360. - Reimbursement and guideline status (e.g., ACS guidelines). - Reimbursement submissions and expected price targets. No explicit figures or statements related to orderbooks or pending orders were disclosed in the text.